Publication date: Available online 27 December 2018
Source: Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology
Author(s): Jun Ishikawa, Fumiya Kano, Yuji Ando, Hideharu Hibi, Akihito Yamamoto
Abstract
Objective
The bone-healing process consists of a primary inflammatory phase and a subsequent anti-inflammatory bone-forming phase. It was recently suggested that macrophages play an indispensable role in bone healing. Macrophages are plastic immune cells consisting of several subtypes, including pro-inflammatory M1-type and anti-inflammatory M2-type macrophages. Recently, a set of M2 macrophage inducers was described, monocyte chemoattractant protein-1 (MCP-1) and the secreted ectodomain of sialic acid-binding Ig-like lectin-9 (sSiglec-9), and applied them to a rat spinal cord injury model. Here, we hypothesized that MCP-1/sSiglec-9 enhance bone regeneration by inducing M2 macrophages.
Methods
We investigated the osteogenic activity of MCP-1/sSiglec-9 in vitro and in the rat calvarial bone defect model.
Results
We found that MCP-1/sSiglec-9 induced M2 macrophagesin vitro, which expressed increased levels of multiple mRNAs that encode osteogenic factors, including Igf-1, Tgf-β, Hgf, Bmp2, and Fgf2. We then demonstrated that MCP-1/sSiglec-9 accelerated bone formation and caused anti-inflammatory M2 macrophages to accumulate in the rat calvarial bone defect in vivo.
Conclusions
Collectively, our data suggest that the local administration of MCP-1/sSiglec-9 promotes bone formation by inducing anti-inflammatory M2 macrophages that express a variety of osteogenic factors. MCP-1/sSiglec-9 may be beneficial in bone regenerative therapy.
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2EU4Drl
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.